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ABSTRACT 
 
Thyroid hormones act directly on transcription by binding to TR1, TRb1, TRb2 nuclear receptors, 
regulating many aspects of post-natal development and homeostasis. To precisely analyze the 
implication of the widely expressed TR1 isoform in this pleiotropic action, we have generated 
transgenic mice with a point mutation in the TR1 coding sequence, which is expressed only after 
CRE/loxP mediated DNA recombination. The amino-acid change prevents interaction between TR1 
and histone acetyltransferase coactivators and the release of corepressors. Early expression of this 
dominant-negative receptor deeply affects post-natal development and adult homeostasis, 
recapitulating many aspects of congenital and adult hypothyroidism, except in tissues and cells where 
TRb1 and TRb2 are predominantly expressed. Both respective abundance and intrinsic properties of 
TRa1 and TRb1/2 seems to govern specificity of action. 
 
INTRODUCTION 
 
Thyroid hormones (TH) consist in 3,5,3’-tri-iodothyroinine (T3) and its precursor thyroxine (T4) 
which displays a weaker biological activity. Both molecules are secreted by thyroid gland follicles, but 
most of T3 synthesis results from T4 deiodination in other organs. T3 binds to nuclear receptor (TRs) 
present as three different isoforms, TRa1, TRb1, TRb2 encoded by the two THRA and THRB genes. 
TRs bind in a ligand-independent manner to specific response elements, mainly as RXR heterodimers, 
which are widespread in the genome. Unliganded TRs recruit transcription corepressors. Among these 
NcoR and SMRT function as platforms for the recruitment of histone deacetylases. T3 binding results 
in a displacement of the C-terminal helix of TR, which contains activation function 2 (AF-2). This 
permits the recruitment of several coactivators complexes, some of them, like SRC1 and SRC2, 
having a histone acetyl-transferase activity (1, 2) and destabilizes interactions with histone deacetylase 
corepressors.  
 
TH signaling exerts multiple effects on post-natal development and the maintenance of 
homeostasis in adults by directly regulating target gene transcription (3). Previous investigations used 
various strategies to decrease TH levels. Among several animal models, transgenic mice recently 
gained popularity, at the expense of thyroidectomized or pharmacologically manipulated rats. In Pax8-
/-
 knockout mice, the only reported primary defect is the absence of thyroid follicular cells (4). 
Although these animals can receive maternal TH through placenta during fetal development, they 
usually die within three weeks after birth, unless they are rescued by TH treatment. The direct and 
indirect effects of congenital hypothyroidism are difficult to unravel. TR knockouts mice offered new 
possibilities to solve this problem and allowed attributing specific function to each receptor isoform 
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(5). The broadly expressed TR1 appears to be the main regulator of development during the first 
three weeks of post-natal, pre-weaning development. This period, somewhat reminiscent of amphibian 
metamorphosis (6), is marked by a transient increase in TH circulating level. At this time, liganded 
TR1 regulates intestinal remodeling (7), cerebellum development (8), spleen erythropoiesis (9) and 
bone growth (10). TR1 has a later role in setting cardiac function (11) and thermogenesis. TRb1 and 
TRb2 expression pattern is more restricted. These isoforms are the main regulators of liver function, 
inner ear development, retinal cones differentiation, and feedback regulation of the hypothalamic-
pituitary-thyroid axis.  
 
Surprisingly the deletion of all TR isoforms, obtained by the combination of THRA and THRB 
knockouts, is not lethal and only partially recapitulates the post-natal consequences of congenital 
hypothyroidism observed in Pax8-/- mice (12, 13). Several studies support the hypothesis that this 
discrepancy is due to the negative effect exerted by the unliganded TR1 present in hypothyroid Pax8-
/-
 mice, but not in THRA/THRB knockout mice. In line with this, the consequences of TH depletion are 
attenuated when THRA is deleted (8, 14). Furthermore the consequences of THRA knockout are 
limited compared to those of THRA knock-in mutations. Three germline knock-in mutations have been 
introduced in the ligand binding domain of TR1. The reading frame mutations have different 
consequences on ligand binding and cofactor interactions, but all preserve DNA binding and reduce 
the transcriptional activation ability of TR1. Mice heterozygous for these mutations display many 
features of congenital hypothyroidism, suggesting a constitutive repression of TH target genes (15-18). 
The hypothesis that congenital hypothyroidism is mainly due to the negative action of unliganded 
TR1 remains however controversial for several reasons. First, the rescue of Pax8-/- mice by THRA 
knockout is only partial, and not observed with all THRA alleles (19). Another difficulty is that the 
consequences of the three THRA knock-in mutations are not identical. For example, obesity has been 
reported in only one case. For these reasons, several additional hypothesis have been proposed, 
including the intervention in hypothyroid mice of unliganded TRb (20), of TRa2, a THRA encoded 
isoform which is unable to bind T3 (19), or of TH non-genomic effects (21, 22).  
 
We describe here the construction of a new mouse allele for the THRA gene, encoding a TR1 
receptor with an AF-2 mutation (L400R). According to structural data, the mutation fills a cavity at the 
surface of the ligand binding domain which is required for histone acetyl transferase coactivators 
interaction. The mutation prevents histone acetyl transferase recruitment and favours the permanent 
recruitment of corepressors. This is responsible for a dominant negative activity exerted on both TR1 
and TRb receptors in transient expression assays. The genetic construct introduced by homologous 
recombination in the THRA locus possesses an upstream floxed cassette, allowing for a spatio-
temporal expression control of TR1L400R expression, using the Cre/loxP recombination system. The 
-4- 
phenotypic consequences of an early embryonic recombination of this THRA allele on development 
and homeostasis closely resemble those of congenital and adult hypothyroidism, except in tissues 
where THRB function is predominant. We conclude that, although hypothyroidism manifestations 
mainly results from to the negative action of the ubiquitous unliganded TR1, unliganded TRb also 
contribute in several tissues. 
 
RESULTS 
 
Construction of the TRaAMI allele  
We introduced in the AF-2 domain of the mouse TR1 receptor a point mutation converting a leucine 
into an arginine (L400R) equivalent to the L454R mutation previously created in the human TRb1 (23, 
24). It has been shown previously that this TRb1 mutation fully prevents interaction with the histone 
acetyl transferase coactivators while preserving interaction with histone deacetylase corepressors (34), 
resulting in a very strong dominant-negative activity on TR mediated transactivation. Recently, this 
mutation has also been shown to prevent an interaction between AF-2 and the hinge region, but the 
functional significance of this interaction remains unclear (25). We verified, using a proteolysis 
sensitivity assay, that ligand binding was not abolished by the mutation (data not shown). We used 
yeast two-hybrid assays to confirm that, whether T3 is present or not, TR1L400R interacts with the 
NcoR histone deacetylase corepressor but not with the SRC1 or SRC2 histone acetyl transferase 
coactivators (Figure 1A). We then introduced the TR1L400R cDNA between two cassettes. The 
downstream IRESTaulacZ cassette encodes a b-galactosidase targeted to the cytoskeleton, translated 
from an ECMV internal ribosomal entry site. We placed the entire construct downstream to a CMV 
transcription promoter (figure 1B) to perform transient expression assays. The upstream 
PGKNeoRpolyA cassette confers G418 resistance to eukaryotic cells and contains a SV40 
polyadenylation signal, which arrests most transcription and prevents any TR1L400R translation. As 
the upstream PGKNeoRpolyA cassette is flanked by two tandem loxP sequences, CRE mediated 
recombination is required to produce a bicistronic mRNA encoding both TR1L400R and b-
galactosidase. This design was expected to favor the detection of recombination events in mouse 
tissues by Xgal staining. Transient expression results confirm that synthesis of both TR1L400R protein 
(Figure 1C) and b-galactosidase (data not shown) requires previous excision of the PGKNeoRpolyA 
cassette. TR1L400R was not able to activate transcription via a T3 response elements (2xDR4), and 
exerted a strong dominant negative effect on transcriptional activation mediated by the wild-type 
liganded TR1 receptor (Figure 1D). A similar dominant-negative action was observed when TRb1 or 
TRb2 was used for transactivation (data not shown). All these observations lead to the conclusion that 
the L400R mutation places the TR1 receptor in a conformation, equivalent to the unliganded state, 
that exert a constitutive dominant-negative effect on TR target genes expression. 
-5- 
 
 The TR1L400R reading frame flanked by the upstream PGKNeoRpolyA and the downstream 
IRESTaulacZ cassettes, was introduced in the mouse THRA locus by homologous recombination 
(Figure 2A,B). In the resulting TRaAMI allele (AF-2 Mutation, Inducible), the mutation is silent. CRE 
recombination is required to express TR1L400R from its natural promoter, at a level similar to the 
endogenous TR1 receptor. To address the ability of ES cells to express TR1L400R after CRE 
recombination, CRE was transiently expressed in TRaAMI/+ ES cells and RT-PCR was performed to 
amplify the 3’ part of the TR1 cDNA. As TR1L400R cDNA differs from its wild-type counterpart by 
the presence of a SacII restriction site we digested the PCR product with SacII and confirmed by gel 
electrophoresis the presence of both type of mRNA in TRaAMI/+ ES cells after CRE recombination 
(Figure 2C). ES cells carrying an intact TRaAMI allele were injected into blastocytes to produce mouse 
chimeras. After germline transmission, TRaAMI/+ mice, which express only one intact THRA allele, 
were obtained. They displayed, as expected, a normal growth and fertility and an apparently normal 
phenotype. TRaAMI/TRaAMI animals, which do not express any THRA isoforms, were obtained at the 
next generation. These homozygous animals, whose phenotype was not investigated, were able to 
develop and breed normally, like other THRA knockout mice.  
 
Early and ubiquitous expression of TR1L400R leads to a hypothyroid-like phenotype 
To trigger a broad expression of TR1L400R we crossed TRaAMI/+ mice with SYCP1CRE transgenic 
mice. These mice have been reported to express the CRE recombinase only during male 
spermatogenesis (26). We thus expected TRaAMI/+xSYCP1CRE males to give rise to progenies where a 
deleted TRaAMI allele would be in all cells from the beginning of development, and TR1L400R 
expressed ubiquitously. Unlike previous reports, we found that complete excision did not occur in all 
cases, some TRaAMI/+xSYCP1CRE males giving rise to offspring with no or partial excision. To 
circumvent this problem, probably due to variegation in CRE expression, we selected favorable 
TRaAMI/+xSYCP1CRE males for further experiments and only considered pups with excision 
efficiency, as evaluated by PCR, superior to 90% (Figure 3A). We will call these heterozygous mice, 
which express TR1L400R in most tissues, TRaAMIxS. We performed RT-PCR to demonstrate the 
presence of a SacII containing TR1L400R cDNA in several tissues (data not shown). Q-RT-PCR was 
also used to evaluate the total expression level of TR1 (TR1L400R+wild-type) in TRaAMIxS mice. The 
expression level at P15 was similar to the one observed in wild type animal in liver with a 3-fold 
increase in the cerebellum (Table I) and brain (data not shown). This slight augmentation could result 
from the absence of alternate splicing in the TRaAMI locus, a phenomenon that normally diverts part of 
the THRA transcription to produce TRa2, an isoform which does not bind T3. b-galactosidase activity 
was very weak or undetectable, probably due to low expression level of the THRA locus, and perhaps 
to limited efficiency of translation initiation at the IRES element.  
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At P15 the fraction of TRaAMIxS in litters was close to the expected 50% ratio. It seems therefore that 
expression of the TR1L400R expression is compatible with pre-natal and early post-natal development 
of heterozygous mice. By contrast later development was deeply affected, and 48% of the TRaAMIxS 
pups did not reach the adult age (N=61). The development of surviving mice was strongly delayed. 
Eye opening did not occur before P25, compared to an average of P15 for wild-type littermates. Body 
growth was greatly reduced (Figure 3B). This correlated with delayed ossification of long bones 
(Figure 3C), and reduced growth hormone gene expression level in pituitary gland (Table I). After 
weaning, the body weight of the surviving mutant mice increased, but the adults suffered from 
permanent and disproportioned dwarfism. Measurement of body fat content by nuclear magnetic 
resonance did not reveal any increase in adiposity (Table I) also intraperitonal content in white adipose 
tissues was found to be strongly reduced, when 4 weeks-old and 3 months-old animals where 
dissected. TRaAMIxS females were sterile, without obvious histological defects in ovaries (data not 
shown).  
 
Beside dwarfism, TRaAMIxS animals displayed several other features of congenital 
hypothyroidism. This was the case in the spleen (Table I), whose weight was highly reduced at P15. In 
the cerebellum, the external granular layer, a transient structure which normally disappears at earlier 
stage, persisted at P21 (Figure 3D). The expression level of genes sensitive to hypothyroidism, 
Hairless in granular neurons and Pcp2 in Purkinje cells was significantly reduced (Table I). Signs of 
cerebellar defect were also observed in adult TRaAMIxS mice, which displayed a characteristic ataxia 
bearing, spreading their hindlimbs to maintain their posture. Adult TRaAMIxS mice had reduced heart 
rate (Table I) and sometimes displayed cardiac arythmia. This cardiac phenotype correlated with a 
decreased expression at P15 for two T3 target genes, the potassium channel encoding genes HCN2 and 
KCNB1 (Table I). The body temperature was usually close to normal in TRAMIxS mice (Table I). 
However, a cold tolerance test revealed, like in mice lacking all TR isoforms (27) a defect in 
thermogenesis ability, the body temperature of TRaAMIxS mice dropping within few hours after cold 
exposure for a fraction of animals (Figure 3E). T3 and T4 levels were not changed in TRaAMIxS mice 
(Table I). The previously observed phenotypic alterations, which are all reminiscent of 
hypothyroidism, are thus not indirect consequences of a central deregulation of TH secretion but 
consequences of peripheral TR1L400R expression. 
 
TRb expressing cells are less sensitive to TR!1L400R expression 
Previous genetic analysis underlined a predominant function of TRb1 and TRb2 receptors in several 
TH functions, including feedback-regulation of TSH secretion from pituitary thyrotropes and 
metabolic control in hepatocytes. TRb1 is also involved in inner ear hair cells, retina cones and 
cerebellum Purkinje cells differentiation. Whether this results from predominant expression of THRB 
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over THRA in these cell types or from intrinsic properties of TRb receptors is unclear. Circulating 
level of TSH (data non shown) and TSHb expression in pituitary (Table I) were not significantly 
affected at P15 in TRaAMIxS mice. In liver, Q-RT-PCR failed to demonstrate a significant change in 
expression level for two TH target genes at P15: Dio1, encoding type 1 deiodinase and Me3, encoding 
the NADP dependent malic enzyme (Table I). Similarly, Q-RT-PCR measurement of opsin gene 
expression failed to reveal a loss of M-Opsin cones in retina (data not shown), suggesting that, unlike 
TRb knockout mice, TRaAMIxS are not colour blind. Purkinje cells differentiation was addressed by 
observing dendritic arborization after calbindin-D28k immunostaining and by measuring Pcp2 mRNA 
level in cerebellum. These two parameters revealed a defect in differentiation at P15 (Figure 3F, table 
I). However, unlike what is reported for hypothyroid animals, this was followed by an apparent 
recovery at P21 (data not shown). TRb1 function was also analyzed in the inner ear. Interestingly, it 
has been shown previously that, in outer hair cells, TRa1 and TRb1 can fulfill distinct functions. 
TRa1 regulates Kcnq4 a potassium channel, while TRb1 activates Slc26a5 expression, a gene 
encoding a motor protein called prestin (28). In line with this, immunocytochemistry revealed that the 
level of KCNQ4, but not of prestin, was highly reduced in TRaAMIxS mice (figure 4). All these 
observations reveal that TRaAMIxS mice do not display all the features of acute congenital 
hypothyroidism and that some TRb prevalent functions are preserved.  
 
Tamoxifen induction of TR!1L400R expression.  
In order to evaluate the possibility to perform a kinetic study of TR1L400R effect on development, we 
crossed TRaAMI/+ mice with CagCreERTM mice, that broadly express a modified CRE recombinase, 
which enzymatic activity is inducible by tamoxifen (29). The resulting heterozygous conditional 
mutants (TRaAMIxC) were treated at E17.5 with tamoxifen. This resulted in the excision of the 
PGKNeoRpolyA cassette in most tissues. The excision efficiency varied from one tissue to the other 
(Figure 5A). In general the phenotype of tamoxifen treated TRaAMIxC animals was similar to the one of 
TRAMIxS, but less severe. This conclusion was based on observations of growth curves (Figure 5B), 
ossification at P15 (Figure 5C), cerebellum histology (Figure 5D), adult heart rate, expression level at 
P15 of KCNB1 and HCN2 in heart, and Hairless and Pcp2 in cerebellum (Table I). This demonstrates 
that expression of TR1L400R, even when started at a late fetal stage, is sufficient to affect post-natal 
development. The relatively mild phenotype of tamoxifen treated TRaAMIxC pups, compared to 
TRAMIxS, might only reflect the incomplete excision of the floxed cassette. We also performed 
tamoxifen treatment in adult TRaAMIxC mice, to overcome detrimental effect of early TR1L400R 
expression. This treatment did not have any visible effect in the short term cold tolerance assay, either 
because recombination efficiency was not sufficient in brown adipose tissue, or because the 
thermosensitive phenotype observed in TRaAMIxS might result from a developmental alteration. 
Nevertheless, tamoxifen treatment of adult TRaAMIxC males induced a significant reduction in heart 
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rate (Figure 3E) indicating that at least this last alteration is not a long term consequence of some 
developmental defect. TRaAMIxC mice therefore appear as a suitable model to separate between the 
developmental and adult homeostatic function of TRa.  
 
DISCUSSION 
 
In this report we describe for the first time a CRE inducible system able to express a dominant 
negative mutation of TR1L400R. TR1L400R is equivalent to an unliganded TR1 receptor, as it 
prevents interactions with histone acetyl transferase transcription coactivators in a highly specific 
manner, without compromising interaction with corepressors. The first practical advantage of CRE 
dependent expression is to permit an easy production of mutant offspring, as the mutated receptor is 
not expressed in breeding animals. This also rules out that the maternal expression of the mutation 
indirectly influences the development of pups. This is expected for example for neuronal migration in 
the cortex (30). This experimental design also opens a broad field for new investigations of TH 
signaling in mice, as the use of tissue specific promoter and of an inducible version of the CRE will 
permit to control the expression of TR1L400R during development and in adults. This will permit to 
separate between the direct and indirect effects of TH signaling, as illustrated here for the cardiac 
function. As a large number of mice expressing CRE or an inducible version of CRE, have been 
already generated worldwide (31), this appears as a highly flexible method to create new animals 
models. These animals will be specifically affected in one or several of the functions sensitive to 
TR1L400R expression, within only one generation time. These functions include, in addition to those 
studied above, lipid storage in white adipose tissue (32), intestinal maturation (33), early post-natal 
erythropoiesis (9), lymphopoiesis (34) muscle function (35), myelin formation (36) and regeneration 
(37), hearing onset (38) , adult brain stem cells proliferation (39, 40), anxiety control and memory 
(41).  
 
Three other THRA knock-in mutations have been reported before, which affect the TRa1 ligand-
binding domain in different manner. Unlike the TR1L400R mutation, whose design was based on 
structural considerations, the changes in the TR1 reading frame were copied from THRB germline 
mutations found in patients with resistance to thyroid hormone. Comparisons between TRaAMIxS and 
the previously reported THRA knock-in mouse strains enable to define constant features among the 
multiple consequences of expressing a dominant negative TR1. As far as we can tell, the TRaAMIxS 
mice phenotype appears to be very similar to those reported for mice carrying the TR1R384C, which 
reduces the affinity of the ligand binding domain for T3 (15) and the TR1PV mutation, a frameshift 
mutation resulting in the loss of the N-terminal AF-2 domain (16, 42, 43). The fourth reported knock-
in mutation, TR1P398H, is the only one that induces obesity and not dwarfism. From our data, we can 
rule out that this peculiar phenotype results from the inability of TR1P398H to recruit histone acetyl 
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transferase coactivators or release corepressors. It has been suggested that TR1P398H/+ obesity rather 
results from a cross-talk between TR1P398H and PPARa  in liver (44) (45). However a similar cross-
talk with PPARg  in white adipocytes has been proposed to explain the opposite phenotype in 
TR1PV/+ mice (42). Many human germline point mutations that prevent histone acetyl transferase 
recruitment have been reported for THRB, but not for THRA. From these studies we can predict that an 
AF-2 mutation in the human TR1 receptor would have dramatic consequences on development even 
at the heterozygous state.  
 
The phenotypic similarities between TRaAMIxS and Pax8-/- hypothyroid mice demonstrate that the 
ligand-mediated recruitment of histone acetylase coactivators and/or release of corepressors by TR1 
is crucial for post-natal development. This strengthens the previous conclusion that congenital 
hypothyroidism is mainly a manifestation of the negative action of unliganded TR1 (14). However 
differences are found between TRaAMIxS and Pax8-/- animals, suggesting a more complex situation. For 
example, the majority of TRaAMIxS survive beyond weaning, while Pax8-/- mice usually die within 
three weeks after birth. Our data suggest that in cells where THRB is highly expressed, like 
thyrotropes, hepatocytes, and retina cones, liganded TRb can balance the down-regulation exerted by 
TR1L400R. Such a compensation cannot take place in hypothyroid mice, where unliganded TRb 
receptors might instead participate to negative gene regulation and further compromise post-natal 
development. The presence of liganded TRb in TRAMIxS can explain all the differences observed with 
Pax8-/- hypothyroid mice, leaving little place for the proposed intervention of the antagonist TR2 
isoform (19) or of an hypothetical TR independent TH signaling pathway (21, 46). It seems therefore 
that unliganded TR1, and to a lesser extent unliganded TRb, can account for all the detrimental 
effects of hypothyroidism in juveniles and in adults. 
 
One important question that our data can help to clarify is whether the individual functions of TRa1 
and TRb1/2 isoforms in a given cell type are dictated by their respective abundance or by differences 
in their intrinsic properties. A vast amount of in vitro data suggests that TRa1 and TRb1/2 are, at least 
at first sight, functionally equivalent. Knockout observations strengthen this hypothesis, as the 
phenotypic differences observed between THRA and THRB individual knockouts mainly reflect their 
contrasting expression patterns. Combinations of THRA and THRB knockout mutations also suggest 
functional redundancy, as several phenotypic alterations augmented (3, 47). As expected TR1L400R 
exerts in transient expression assays a dominant-negative action both on TRa1 and TRb1. 
Accordingly, most features of the TRaAMIxS phenotype can be predicted from the respective abundance 
of THRA and THRB encoded receptors in a given cell type. First, we failed to detect any phenotypic 
alteration in cell types known to express THRB at much higher level than THRA. This includes retina 
cones, hepatocytes and thyrotrope cells. Second, TRb receptors appear sensitive to the TR1L400R 
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dominant-negative effect in tissues where the stochiometry is less favorable to THRB. Previous genetic 
studies have shown that compound knockout mice devoid of all receptors have a reduced body 
temperature and are much more sensitive to cold exposure than THRA knockout mice (27, 48, 49). 
Thus, despite pharmacological evidences indicating only partial overlap (50), the functions of the two 
receptors seem to be redundant for cold resistance, correlating with the concomitant presence of TR1 
and TRb1 in brown adipose tissue (51). The fact that TRAMIxS are highly sensitive to cold exposure 
therefore suggests that TR1L400R can interfere with both TR1 and TRb1 functions in brown 
adipocytes. A similar interpretation can be proposed for Purkinje cells. Hypothyroidism results in a 
permanent reduction in dendritic arborization and a disorganization of the cells alignment (52). In situ 
hybridization reveals a predominant THRB expression in these cells after birth (53), and their 
differentiation is deeply affected by a TRb knock-in mutation (20). However, in vitro differentiation of 
purified Purkinje precursors rather suggests a predominant function for TR1 over TRb1 (54). We 
show here that TR1L400R, like TR1R384C (41) has only a transient effect on Purkinje dendrites 
arborization. A possible explanation would be that, as THRB expression increases over time in this cell 
type (55), TRb1 progressively accumulates, overcomes the transcription repression exerted by 
TR1L400R and eventually unlocks differentiation. In conclusion, expression patterns clearly influence 
the respective in vivo function of TRa1 and TRb1/2.  TR stochiometry is however unlikely to be the 
only explanation for the maintenance of several TRb1/2 dependent functions in TRAMIxS mice. Some 
our results also suggest that TRa1 and TRb1/2 intrinsic properties, and the set of target genes that they 
control, are different. For example, the resting body temperature of most TRAMIxS animals is normal, 
unlike what is reported for compound THRA/THRB knockout mice, suggesting that part of the 
activation by TRb1 is preserved in brown adipocytes. Most importantly, the inner ear phenotype 
provides compelling evidence that TRa1 and TRb1 intrinsic properties are different. Within outer hair 
cells, TR1L400R appears to antagonize TR1 driven transactivation of KCNQ4 without compromising 
TRb1 mediated regulation of prestin. It seems therefore that in vertebrates, divergent evolution of the 
paralogous THRA and THRB genes increased the variety of cellular responses to TH.  
 
MATERIAL AND METHODS 
 
Plasmids and transient expression assays 
The L400R mutation was introduced in the TR1 reading frame present in the pBIRDTRa1 construct 
(56) using for PCR mutagenesis an oligonucleotide containing a SacII restriction site at the mutation 
site: 5’ CC CCG CGG TTC CTG GAG GTC TTT GAG 3’. The entire cDNA structure was confirmed 
by DNA sequencing. The mutated cDNA was inserted between a floxed PGKNeoRpolyA (57) able to 
stop transcription, and an IRESTaulacZ sequence (58) to create a bicistronic mRNA encoding both the 
mutated receptor TR1L400R and the reporter Tau-b-galactosidase fusion protein targeted to the 
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cytoskeleton. The completed construct was transferred as a PacI restriction fragment into the pBK-
CMV expression vector (Stratagene San Diego) (figure 1B) or between two large genomic fragments 
(Figure 2A) cloned into the Supercos1 cosmide vector (Stratagene) for homologous recombination. An 
identical pBK-CMV derivative was made for the intact TRa1 cDNA for control experiments. For 
transient expression, Cos-7 cells, maintained in TH depleted medium, were transfected with Exgen 
reagent (Fermentas). pTK-DR4(2x)-luc was used as a reporter construct (59) and pRL-CMV 
(Promega), encoding renilla luciferase, as an internal standard. T3 (10-7M) was eventually added to the 
medium 24h before the quantification of luciferase activity (Promega, Dual Luciferase Assay). The 
full-length TRa1 and TR1L400R reading frames were transferred into pAS2.1 (Clontech) to perform 
two-hybrid assays in yeast cells. Two-hybrid interactions were tested by plating AH109 yeast cells on 
selective medium and quantified by measuring b-galactosidase activity in Y187 yeast cells, using 
orthonitrophényl- -D-galactopyrannoside as a substrate.  
 
Generation of mutant mice 
The oligonucleotides used for vector construct, screening and TR expression analysis are the 
following (positions on figure 2). a: 5’GCGATACCGTAAAGCACGAG ; b : 
5’GCCTTCTATCGCCTTCTTGACG ; c : 5’CGTCTGGAGAAGAGTTGG d : 5’ 
TCCACAGGTATCTCCAGACAGG e : 5’ GATTCTTCTGGATTGTGCGGCG f : 
ACCGCAAACACAACATTCCGCACTTCTGGC g : 5’ GAGGAAGGAGAGAAGAGATG 
GGGGTTC h : 5’ CGGTCGCTACCATTACC AGTTG i : 5’ TTATGGATGGACGGACGG j : 5’ 
AGTCTACGGCAAGGCAACACCAAG. 5x106 129/Sv mouse embryonic stem cells (13) were 
electroporated with 40 µg of linear plasmid and selected with G418 (250 µg/ml; Gibco-BRL). Cell 
clones were picked 10 days later and screened by PCR amplification of junction fragment, using Long 
expand Taq polymerase (Roche) (a+c for the 5’ side, h+j for the 3’ side). 3 out of 310 clones carried 
the mutant allele called TRAMI(AF-2 Mutation, Inducible). After further PCR characterization of the 
recombinant allele, cells were injected into C57/Bl6 blastocysts to generate chimeras. After germline 
transmission, transgenic mice were routinely screened by PCR directed on the lacZ – exon 9 junction 
(h+i). TRAMIxS and TRAMIxC mice were produced by crossing TRAMI/+ mice with SYCP1CRE 
transgenic mice (26) and CagCreERTM (29) respectively and identified by PCR 
(5’TTACCGGTCGATGCAACG3’+ 5’CCAGCCACCAGCTTGCAT3’ for CRE). When indicated, 
TRAMI/C mice received 1 (pregnant E17 mothers) or 5 (adults) daily intra-peritoneal injection of 
tamoxifen (Sigma T-5648, 50 mg/kg) dissolved in corn oil. CRE mediated deletion was identified by 
PCR (b+d+e). All animals experimentations were performed under Animal care procedures and 
conducted in accordance with the guidelines set by the European Community Council Directives 
(86/609/EEC). 
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Phenotype analysis 
RNA were extracted from tissues of 8-10 mice per group and purified using RNeasy (Qiagen) or RNA 
Nanoprep (Stratagene) extraction kits, including a DNaseI treatment. RNA quality controls were 
performed by gel electrophoresis (Agilent 2100 Bioanalyzer). cDNA were prepared from 1 µg RNA 
using M-MLV reverse transcriptase (Promega) and random 6-mers primers. After 1/40 dilution, 2 µl 
of cDNA were used for quantitative PCR (Stratagene Mx3000P® QPCR System), using either 
Platinum® Quantitative PCR SuperMix (Invitrogen) or Taqman Assay-on-Demand (Applied 
Biosystems). Quantitation was performed in duplicates using the HPRT and TBP housekeeping genes 
as internal standards (or ARBP for pituitary) and the 2-$$Ct method for data analysis (60). Parrafin 
sections were prepared from tissues fixed with 4% paraformaldehyde. Purkinje cells were stained with 
a rabbit anti-calbindin-D-28k antibody (Swant CB38a, 1/5000 dilution). Serum T4, T3 and TSH levels 
were measured as described previously (61). Cold tolerance assays were performed with a telemetry 
system as previously described (48) in a 4°C room. Body temperature was measured every 15 or 30 
minutes during 8 hours and mice were removed from the cold room when their body temperature 
dropped below 35°C. Inner ear immunocytochemistry was performed as described previously (28).  
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FIGURES 
 
Figure 1: Properties of the TR1L400R mutated receptor  
A: Two-hybrid interactions in yeast show that TR1L400R can only interact with corepressors. Unlike 
liganded TRa1, TR1L400R does not interact with SRC1 and SRC2 histone acetyl transferase 
coactivators. The interaction with the NcoR corepressor is ligand sensitive for TRa1 but constitutive 
for TR1L400R. B: Cytomegalovirus (CMV) and phospho-glycerate-kinase (PGK) promoters generate 
transcripts terminated by the SV40 polyadenylation signal present in the PGKNeoRpolyA cassette. The 
bicistronic TR1L400R and TaulacZ cDNA, located downstream to the SV40 polyadenylation signal, 
cannot be expressed. As the PGKNeoRpolyA cassette is flanked by two loxP sequences, CRE mediated 
deletion enables TR1L400R and TaulacZ synthesis. C: TR1L400R expression requires CRE mediated 
deletion. Western blotting of mammalian COS7 cells transfected with the CMV construct encoding for 
TR1L400R (1, 2) or the empty CMV construct (3). When the floxed PGKNeoRpolyA cassette is present 
(1), only a non-specific band is detected, reflecting the absence of TR1L400R expression. The CRE 
deleted construct (2) encodes the expected 44 kDa TR1L400R protein. D: TR1L400R acts as a dominant 
negative receptor. Transient luciferase expression in transfected COS7 cells show that, unlike wild-
type TR1, TR1L400R can not transactivate a DR4-TK-luc construct in the presence of T3. TR1 
mediated transactivation is antagonized by increasing amount of TR1L400R. A 1/1 ratio leads to a 
complete inhibition of T3 response.  
 
Figure 2: Generation of the TRaAMI allele by homologous recombination in mouse embryonic 
stem cells. A: Structure of the THRA locus after homologous recombination. From 5’ to 3’: THRA 
sequences absent from the recombination vector (black line) 6,5kb of THRA genomic sequences 
extending to the non coding part of exon2 (nucleotide 279 on Genebank # NC_000077 dark grey box); 
the PGKNeoRpolyA cassette, providing G418 resistance to ES cells, flanked by two tandem loxP for 
CRE mediated deletion; TR1L400R encoding sequence; ECMV-IRES element for internal ribosomal 
entry; TaulacZ coding sequence; 2.9 kb of THRA, starting in exon 9 (nucleotide 22889 on Genebank # 
NC_000077 dark grey box), 3’ genomic sequences absent from the recombination vector (black line). 
White arrows indicate the position and orientation of oligonucleotides used for PCR amplification. 
The SacII restriction site covers the L400R encoding codon. CRE mediated recombination results in 
the deletion of the floxed selection cassette, allowing for transcription and translation of the 
downstream TR1L400R and TaulacZ reporter protein. B PCR confirmation of homologous 
recombination in the THRA locus in ES cells. Primers a and c amplify a 10.8 kb fragment (2) while h 
and j amplify 3.3 kb (4) after homologous recombination but not after random DNA integration (1 and 
3). C CRE mediated recombination in TRaAMI/+ ES cells triggers TR1L400R expression. RT-PCR of 
RNA purified from ES cells (primers f and g) amplifies 274 bp of TR1 cDNA (*) and a non specific 
product (***). SacII digestion releases two fragments (135bp+139bp **) in ES cells carrying one 
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CRE-deleted TRAMI allele (3). TR1L400R expression is not detected in ES cells carrying wild-type 
alleles (1) or one intact TRAMI allele (2). 
 
Figure 3: phenotype of TR!AMIxS mice  
A TRAMIxS mice have lost the PGKNeopolyA cassette. PCR was performed on tail DNA with primers 
b,d,e (Figure 2) amplifying either 1200bp (b+e) for the full length TRAMI allele or 800bp (d+e) for the 
CRE deleted TRAMI allele. Due to the presence of intronic sequences, the intact THRA locus can not 
be amplified in these conditions. B Body growth reduction in TRAMIxS mice compaired to wild-type 
littermates. Body weight (g) was measured during 80 days (N=22). C Alizarine staining, performed on 
whole mount skeleton, reveals delayed ossification of long bones (arrow) in TRAMIxS mice at P15, 
clearly visible in posterior limbs. D Delayed cerebellum development in TRAMIxS mice: sagital 
section shows the persistence of the external granular layer (arrows) at P21 in TRAMIxS cerebellum 
(haematoxylin staining) but not in control littermates. E Cold tolerance test: The body temperature of 5 
TRAMIxS 5-months old adult females (black lines) and 4 control female littermate (grey lines) was 
recorded during 8 hours of cold exposure. 3 out of 5 animals failed to maintain their body temperature 
within this time period. F Purkinje cells dendritic arborization, revealed by calbindin-D28k staining, is 
visible above cell nuclei. The number and size of dendritic spines is reduced at P15 in TRAMIxS 
cerebellum.  
 
Figure 4: Inner ear phenotype of TR!AMIxS mice 
Immunohistochemistry reveals the presence of both prestin and KCNQ4 (red) in wild-type outer hair 
cells (OHC) at P15. The same observation was performed on 3 TRAMIxS mice and 4 wild-type mice. 
Small arrows underline basolateral staining for prestin, and perinuclear staining for KCNQ4. Vertical 
arrows indicate the positions of cells nuclei, counterstained with 4',6-diamidino-2-phenylindole 
(DAPI, blue). Whereas prestin staining is maintained, perinuclear KCNQ4 staining is lost in TRAMIxS 
mice (*). 
 
Figure 5: phenotype of TR!AMIxC mice 
A-D: Phenotype of TRAMIxC pups born from females treated with tamoxifen at gestational day 17.5. 
A: Deletion of the PGKNeoRpolyA cassette after tamoxifen treatment at E17.5, analyzed by PCR at 
P15 (primers b, d, e Figure 2) reveals the presence of a 800bp fragment (*) corresponding to the CRE 
deleted TRAMI allele in cerebellum (cb) whole brain (wb) and small intestine (si) in TRAMIxC mice 
(+), but not in control littermates without CRE transgene (-). The upper 1200bp band corresponds to 
the full-length TRAMI allele. B Body weight (g) was measured during 138 days (N=10). Body growth 
is less affected in TRAMIxC mice than in TRAMIxS mice (Figure 3B) but significantly reduced 
compared to TRAMI/+ littermates, which do not express the mutation. C Alizarine staining performed 
on whole mount skeleton reveals delayed ossification of long bones in TRAMIxC mice at P15. The 
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defect, marked by arrows, is less pronounced than for TRAMIxS mice (Figure 3C). D Persistence of 
external granular layer in cerebellum at P21. Unlike what is found in wild-type controls, granular 
precursor cells (black arrow, here in the groove between lobe IV and lobe V) are still present in 
TRAMIxC, but less abundant than in TRAMIxS. E: Tamoxifen treatment of 8 weeks-old adult males 
induces a significant decrease (p=0.01 Student t test) of heart rate, measured one week later, in 
TRAMIxC (N=7) compared to age matched wild-type controls (N=7), also treated with tamoxifen. 
TRAMIxS data (N=4) are given for comparison.  
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Mouse genotype +/+ TRAMI/+ TRAMIxS TRAMIxC* 
 
Physiological parameters P15 
Serum T4 (µg/dL) 9,3±0,6 9,6±1 9,0±2,4 6,8±2,2** 
Serum T3 (ng/dL) 141±22 168±15 129±13 164±8 
Spleen weight (mg) 39,5±9,1 45,0±10,8 26,9±12,2*** 26,2±7,5** 
 
Physiological parameters in adult males (2 – 3 months) 
Serum T4 (µg/dL) 4,3±0,8 ND 4,2±0,7 ND 
Serum T3 (ng/dL) 116±24 ND 123±12 ND 
Serum TSH (mU/L) † 144±106 ND 50±26 ND 
Heart beat (/min) † 393±45 ND  224±24*** ND  
Body temperature (°C)  38,3±0,4 38,6±0,2 38,5±0,4 38,4±0,5 
Body fat content (%)† 9,33±1,61 ND 8,20±0,36 ND 
 
Gene expression P15 (% of wild type) 
Gene Tissue/organ     
GH pituitary 100±47 142±33 44±20** 52±18 
TSHß pituitary 100±31 171±53** 65±32 120±12 
Dio1 liver 100±17 112±26 101±51 ND 
ME3 Liver 100±38 86±17 130±20 ND 
TR1+TR1L400R liver 100±12 71±15** 94±6 81±13 
HCN2 heart 100±27 76±32 7±2*** 5±2*** 
KCNB1  heart 100±18 87±24 25±6*** 21±7*** 
Hr cerebellum 100±19 132±37 19±5*** 39±11*** 
PcP2 cerebellum 100±21 122±21 38±21*** 105±10 
TR1+TR1L400R cerebellum 100±26 140±29** 327±48*** 374±56*** 
* tamoxifen treated at E17.5 ** different from wild type, p < 0,05  *** p < 0,01 ND = Not Determined  †Males only 
   





